中国高血压联盟 . 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020 , 19(05) : 454 -459 . DOI: 10.16150/j.1671-2870.2020.05.003
| [1] | Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen?[J]. Eur Heart J, 2014, 35(19):1245-1254. |
| [2] | Käyser SC, Dekkers T, Groenewoud HJ, et al. Study hete-rogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis[J]. J Clin Endocrinol Metab, 2016, 101(7):2826-2835. |
| [3] | Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice[J]. J Am Coll Cardiol, 2017, 69(14):1811-1820. |
| [4] | Umpierrez GE, Cantey P, Smiley D, et al. Primary aldo-steronism in diabetic subjects with resistant hypertension[J]. Diabetes Care, 2007, 30(7):1699-1703. |
| [5] | Prejbisz A, Florczak E, Klisiewicz A, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension[J]. Endokrynol Pol, 2013, 64(5):363-367. |
| [6] | Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldo-sterone excretion among subjects with resistant hypertension and symptoms of sleep apnea[J]. Chest, 2004, 125(1):112-117. |
| [7] | Li M, Ge Q, Sheng CS, et al. Clinical characteristics of snoring patients with primary aldosteronism and obstructive sleep apnea-hypopnea syndrome[J]. J Hum Hypertens, 2019, 33(9):693-700. |
| [8] | Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1):41-50. |
| [9] | Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol, 2005, 45(8):1243-1248. |
| [10] | Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5(9):689-699. |
| [11] | Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16):1913-1922. |
| [12] | 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736. |
| [13] | 冷敏, 刘爱云, 司家峰, 等. 化学发光法检测鲁西健康人群肾素-血管紧张素-醛固酮系统参考范围及影响因素[J]. 国际检验医学杂志, 2018, 39(15):1910-1914. |
| [14] | 常富江, 张雪培, 王声政, 等. 醛固酮腺瘤患者血浆醛固酮、肾素水平分析[J]. 检验医学, 2019, 34(8):722-725. |
| [15] | Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldo-steronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38(10):1919-1928. |
| [16] | Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrino-logy Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2016, 175(2):G1-G34. |
| [17] | Wang D, Xu JZ, Chen X, et al. Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography[J]. J Hypertens, 2019, 37(10):2032-2040. |
| [18] | Chen YL, Xu TY, Xu JZ, et al. A speckle tracking echocardiographic study on right ventricular function in primary aldosteronism[J]. J Hypertens, 2020, 38(11):2261-2269. |
| [19] | Rossi GP, Maiolino G, Flego A, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term[J]. Hypertension, 2018, 71(4):585-591. |
| [20] | Farrugia FA, Zavras N, Martikos G, et al. A short review of primary aldosteronism in a question and answer fa-shion[J]. Endocr Regul, 2018, 52(1):27-40. |
| [21] | 陈绍行, 杜月凌, 张瑾, 等. 在高血压患者中筛选原发性醛固酮增多症国人血浆醛固酮/肾素活性比值标准的探讨[J]. 中华心血管病杂志, 2006, 34(10):868-872. |
| [22] | 张炜, 汤正义, 吴景程, 等. 静脉盐水负荷试验在原发性醛固酮增多症诊断中的应用[J]. 上海交通大学学报(医学版), 2007, 27(6):703-705. |
| [23] | Zhang Y, Niu W, Zheng F, et al. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score[J]. J Hypertens, 2017, 35(12):2486-2492. |
| [24] | Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type Ⅱ[J]. Nat Genet, 2018, 50(3):349-354. |
| [25] | Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldo-sterone-producing adenoma[J]. Hypertension, 2015, 65(3):622-628. |
| [26] | Velema M, Dekkers T, Hermus A, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment[J]. J Clin Endocrinol Metab, 2018, 103(1):16-24. |
| [27] | Hundemer GL, Curhan GC, Yozamp N, et al. Renal outcomes in medically and surgically treated primary aldo-steronism[J]. Hypertension, 2018, 72(3):658-666. |
| [28] | Steichen O, Lorthioir A, Zinzindohoue F, et al. Outcomes of drug-based and surgical treatments for primary aldo-steronism[J]. Adv Chronic Kidney Dis, 2015, 22(3):196-203. |
/
| 〈 |
|
〉 |
